Roche touts head-to-head data for Xolair against oral immunotherapy for treating food allergies
A year after the FDA blessed Roche and Novartis’ Xolair (omalizumab) as the first medicine to reduce allergic reactions that can occur from accidental exposure to certain foods, the companies have presented data indicating Xolair may be more effective than oral immunotherapy (OIT) in treating food allergies.
A year after the FDA blessed Roche and Novartis’ Xolair (omalizumab) as the first medicine to reduce allergic reactions that can occur from accidental exposure to certain foods, the companies have presented data indicating Xolair may be more effective than oral immunotherapy (OIT) in treating food allergies.
